Precision Oncology Comes of Age: Tumor-Agnostic Approaches

Colleen Lewis, MSN, ANP-BC, AOCNP®, and R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, presented on the new world of tumor-agnostic treatment approaches, including those aimed at managing patients with tumors that have high microsatellite instability (MSI-H) or neurotrophic receptor tyrosine kinase (N...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, Colleen, Harvey, R. Donald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2020
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857330/
https://www.ncbi.nlm.nih.gov/pubmed/33598315
http://dx.doi.org/10.6004/jadpro.2020.11.3.2
_version_ 1783646427123023872
author Lewis, Colleen
Harvey, R. Donald
author_facet Lewis, Colleen
Harvey, R. Donald
author_sort Lewis, Colleen
collection PubMed
description Colleen Lewis, MSN, ANP-BC, AOCNP®, and R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, presented on the new world of tumor-agnostic treatment approaches, including those aimed at managing patients with tumors that have high microsatellite instability (MSI-H) or neurotrophic receptor tyrosine kinase (NTRK) fusions. Learn about the clinical trial designs that enable development of these novel therapies, and discover how testing methodologies support precision medicine advances.
format Online
Article
Text
id pubmed-7857330
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-78573302021-02-16 Precision Oncology Comes of Age: Tumor-Agnostic Approaches Lewis, Colleen Harvey, R. Donald J Adv Pract Oncol Meeting Reports Colleen Lewis, MSN, ANP-BC, AOCNP®, and R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, presented on the new world of tumor-agnostic treatment approaches, including those aimed at managing patients with tumors that have high microsatellite instability (MSI-H) or neurotrophic receptor tyrosine kinase (NTRK) fusions. Learn about the clinical trial designs that enable development of these novel therapies, and discover how testing methodologies support precision medicine advances. Harborside Press LLC 2020-04 2020-04-01 /pmc/articles/PMC7857330/ /pubmed/33598315 http://dx.doi.org/10.6004/jadpro.2020.11.3.2 Text en © 2020 Harborside™ http://creativecommons.org/licenses/by-nc-nd/3.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Meeting Reports
Lewis, Colleen
Harvey, R. Donald
Precision Oncology Comes of Age: Tumor-Agnostic Approaches
title Precision Oncology Comes of Age: Tumor-Agnostic Approaches
title_full Precision Oncology Comes of Age: Tumor-Agnostic Approaches
title_fullStr Precision Oncology Comes of Age: Tumor-Agnostic Approaches
title_full_unstemmed Precision Oncology Comes of Age: Tumor-Agnostic Approaches
title_short Precision Oncology Comes of Age: Tumor-Agnostic Approaches
title_sort precision oncology comes of age: tumor-agnostic approaches
topic Meeting Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857330/
https://www.ncbi.nlm.nih.gov/pubmed/33598315
http://dx.doi.org/10.6004/jadpro.2020.11.3.2
work_keys_str_mv AT lewiscolleen precisiononcologycomesofagetumoragnosticapproaches
AT harveyrdonald precisiononcologycomesofagetumoragnosticapproaches

Ejemplares similares